Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
US Department of Justice
US Army

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 3,985,758

« Back to Dashboard

Summary for Patent: 3,985,758

Title: 1,4-Dihydropyridine derivatives
Abstract:There are provided novel 1,4-dihydropyridine derivatives, particularly 2,6-dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-.beta.-(N-benzyl-N-methylamino)ethyl ester and 5-methyl ester. The 1,4-dihydropyridine derivatives are characterized by cerebral vascular dilator activity.
Inventor(s): Murakami; Masuo (Tokyo, JA), Takahashi; Kozo (Tokyo, JA), Iwanami; Masaru (Yokohama, JA), Fujimoto; Masaharu (Tokyo, JA), Shibanuma; Tadao (Asaka, JA), Kawai; Ryutaro (Shiraoka, JA), Takenaka; Toichi (Tokyo, JA)
Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, JA)
Application Number:05/584,268
Patent Claim Types:
see list of patent claims

No matches for this query

Foreign Priority and PCT Information for Patent: 3,985,758

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
48-25566Mar 3, 1973
48-52307May 11, 1973
48-83276Jul 24, 1973
48-134070Nov 29, 1973
48-20423Feb 20, 1973
48-44821Apr 20, 1973

International Patent Family for Patent: 3,985,758

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria334898► Subscribe
Austria334902► Subscribe
AustriaA138874► Subscribe
AustriaA824375► Subscribe
Australia6565574► Subscribe
Belgium811324► Subscribe
Canada1023746► Subscribe
Canada1029021► Subscribe
Canada1029022► Subscribe
Switzerland605755► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Cantor Fitzgerald
Chinese Patent Office
Boehringer Ingelheim
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus